Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDx/CDx Focus: Studies Reported At ESMO on Roche's Herceptin, T-DM1, Pfizer's Xalkori
October 03, 2012
MDx/CDx Focus: Studies Reported At ESMO on Roche's Herceptin, T-DM1, Pfizer's Xalkori
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter
Ventana's Growing Companion Dx Focus Mirrors Parent Roche's Investment in Personalized Rx
January 18, 2012 / Pharmacogenomics Reporter
MDx/CDx Focus: Qiagen; Dako & Amgen; Ventana & Pfizer; Foundation Medicine & Sanofi; and More
January 11, 2012 / Pharmacogenomics Reporter
FDA Approves Genentech's Antibody-Drug Conjugate, Marking Third Rx for HER2-Targeted Breast Cancer
February 27, 2013 / Pharmacogenomics Reporter
Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor